Posted by Michael Wonder on 15 Aug 2019
Advanced ovarian cancer drug gets initial 'no' for NHS in England
15 August 2019 - A targeted drug with potential to slow the progress of ovarian cancer has been rejected for use on the NHS in England.
In making its provisional decision on rucaparib (Rubraca), NICE cited a lack of evidence over the treatment's impact on survival.
"NICE felt there wasn't enough evidence to be confident about the drug's long-term benefits, and that the benefit it gave wasn't enough to justify its cost," said Rose Gray, policy manager at Cancer Research UK.
